EGFR and glioblastoma: Another phase I clinical trial that is currently undergoing published preliminary results from three recurrent GBM patients being treated with CARv3-TEAM-E T cells; these are CAR T cells that target EGFR variant III and the wild-type EGFR protein through the secretion of a T-cell–engaging antibody molecule (TEAM) [61].